ArticleInfection and immunity2005
Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13.
Article in Infection and immunity, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 279 citations in OpenAlex.
- Antibiotic-induced Malassezia expansion in the infant gut promotes early-life immune dysregulation and airway inflammation in mice.Nature communications · 2026Article
- The role of the mycobiome in host physiology and disease: insights from rodent models.Lab animal · 2025Review
- Murine gut microbiota dysbiosis via enteric infection modulates the foreign body response to a distal biomaterial implant.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The gut-lung axis: effects and mechanisms of gut microbiota on pulmonary diseases.Frontiers in immunology · 2025Review
- Shaping oral and intestinal microbiota and the immune system during the first 1,000 days of life.Frontiers in pediatrics · 2025Review
- Maternal antibiotic exposure-mediated alterations in basal, and allergen-induced lung function are associated with altered recruitment of eosinophils to the developing lung.Frontiers in immunology · 2025Article
- Profiling inflammatory outcomes ofmBio · 2024Article
- The Microbiota in Children and Adolescents with Asthma.Children (Basel, Switzerland) · 2024Review
- Antibiotic use during influenza infection augments lung eosinophils that impair immunity against secondary bacterial pneumonia.The Journal of clinical investigation · 2024Article
- The intestinal commensal fungus Wallemia mellicola enhances asthma in mice through Dectin-2.Medical mycology · 2024Article
- Lung microbiome: new insights into the pathogenesis of respiratory diseases.Signal transduction and targeted therapy · 2024Review
- The gut-lung axis: the impact of the gut mycobiome on pulmonary diseases and infections.Oxford open immunology · 2024Review
- Gut mycobiome as a potential non-invasive tool in early detection of lung adenocarcinoma: a cross-sectional study.BMC medicine · 2023Article
- Systemic antibiotics cause deterioration of emphysema associated with exaggerated inflammation and autophagy.Experimental & molecular medicine · 2023Article
- The Underrated Gut Microbiota Helminths, Bacteriophages, Fungi, and Archaea.Life (Basel, Switzerland) · 2023Review
- Characterization of Lung Inflammatory Response toJournal of fungi (Basel, Switzerland) · 2023Article
- Dysbiosis of the intestinal fungal microbiota increases lung resident group 2 innate lymphoid cells and is associated with enhanced asthma severity in mice and humans.Respiratory research · 2023Article
- The Fungal and Bacterial Interface in the Respiratory Mycobiome with a Focus onLife (Basel, Switzerland) · 2023Review
- The role of the respiratory microbiome in asthma.Frontiers in allergy · 2023Review
- Friendly fungi: symbiosis with commensal Candida albicans.Trends in immunology · 2022Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Lending support to the hygiene hypothesis, epidemiological studies have demonstrated that allergic disease correlates with widespread use of antibiotics and alterations in fecal microbiota ("microflora"). Antibiotics also lead to overgrowth of the yeast Candida albicans, which can secrete potent prostaglandin-like immune response modulators, from the microbiota. We have recently developed a mouse model of antibiotic-induced gastrointestinal microbiota disruption that is characterized by stable increases in levels of gastrointestinal enteric bacteria and Candida. Using this model, we have previously demonstrated that microbiota disruption can drive the development of a CD4 T-cell-mediated airway allergic response to mold spore challenge in immunocompetent C57BL/6 mice without previous systemic antigen priming. The studies presented here address important questions concerning the universality of the model. To investigate the role of host genetics, we tested BALB/c mice. As with C57BL/6 mice, microbiota disruption promoted the development of an allergic response in the lungs of BALB/c mice upon subsequent challenge with mold spores. In addition, this allergic response required interleukin-13 (IL-13) (the response was absent in IL-13(-/-) mice). To investigate the role of antigen, we subjected mice with disrupted microbiota to intranasal challenge with ovalbumin (OVA). In the absence of systemic priming, only mice with altered microbiota developed airway allergic responses to OVA. The studies presented here demonstrate that the effects of microbiota disruption are largely independent of host genetics and the nature of the antigen and that IL-13 is required for the airway allergic response that follows microbiota disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.